Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger

High Alpha Professor Investing Group Follow Summary Palvella Therapeutics, Inc. advances QTORIN rapamycin for microcystic lymphatic malformations, completing NDA submission with strong Phase 3 data and FDA rolling review. Regulatory risk is now significantly reduced, with the FDA awarding a third year of OOPD funding post-positive Phase 3 results and no further efficacy studies required. PVLA’s robust $250.6 million cash position supports manufacturing, regulatory, and launch efforts ahead of a targeted US commercial launch in H1 2027. I raise the approval probability to 90%, increasing the mLM-only value to $4.0 billion and reiterate a Buy rating with a ~20% higher price target. Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More » Images By Tang Ming Tung/DigitalVision via Getty Images Investment Thesis I covered Palvella Therapeutics, Inc. ( PVLA ) in March. At that time, QTORIN rapamycin had already produced strong Phase 3 data in microcystic lymphatic malformations. My main concern was that it This article was written by High Alpha Professor 565 Followers Follow Dubai-based investor focused on building a resilient, income-generating portfolio with a long-term growth mindset. My approach is primarily long-only, blending dividend-paying equities, REITs, and other income strategies with selective growth opportunities. I believe in disciplined, fundamentals-driven investing, prioritizing capital preservation while compounding returns over time. Originally from India. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.